400 related articles for article (PubMed ID: 3549878)
21. [Comparison between the effectiveness of fluphenazine decanoate and oxyprothepin decanoate in schizophrenia (double-blind crossover study)].
Balon R; Kabesh Ia; Papezhova G
Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(1):116-8. PubMed ID: 6121437
[TBL] [Abstract][Full Text] [Related]
22. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV
Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
Wiles DH; McCreadie RG; Whitehead A
Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
[TBL] [Abstract][Full Text] [Related]
24. [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia].
Ushakov IuV; Kravchenko NE; Kopeĭko GI; Kalugina LI; Mirzoian MG
Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(7):99-104. PubMed ID: 1979463
[TBL] [Abstract][Full Text] [Related]
25. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
Schooler NR; Levine J
Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
[TBL] [Abstract][Full Text] [Related]
26. The response of untreated chronic schizophrenics to haloperidol and haloperidol decanoate.
Leff JP; Tress KH
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():27-40. PubMed ID: 3559160
[TBL] [Abstract][Full Text] [Related]
27. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
Altamura AC; Mauri MC; Girardi T; Panetta B
Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
[TBL] [Abstract][Full Text] [Related]
28. [Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)].
Lehmann E; Quadbeck H; Tegeler J; Fararuni M; Heinrich K
Pharmakopsychiatr Neuropsychopharmakol; 1980 May; 13(3):117-29. PubMed ID: 7393998
[TBL] [Abstract][Full Text] [Related]
29. Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology.
Wistedt B; Ranta J
Acta Psychiatr Scand; 1983 Jun; 67(6):378-88. PubMed ID: 6349256
[TBL] [Abstract][Full Text] [Related]
30. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
Wistedt B; Palmstierna T
J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
[TBL] [Abstract][Full Text] [Related]
31. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
Brown WA; Silver MA
J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
[TBL] [Abstract][Full Text] [Related]
32. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
[TBL] [Abstract][Full Text] [Related]
33. [Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate].
Viala A; Aymard N; Leyris A; Caroli F
Therapie; 1996; 51(1):19-25. PubMed ID: 8762216
[TBL] [Abstract][Full Text] [Related]
34. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
35. [Evaluation of clinical usefulness of decaldol (haloperidol decanoate) produced by WZF Polfa in Warsaw in long-term treatment of schizophrenia].
Morasiewicz J; Baranowski P; Borys J; Jańska-Skomorowska M; Kiejna A
Psychiatr Pol; 1995; 29(3):405-20. PubMed ID: 7652093
[TBL] [Abstract][Full Text] [Related]
36. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
[TBL] [Abstract][Full Text] [Related]
37. [Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol].
López Ibor JJ; Ayuso JL; Gutiérrez M; Guimon J; Herraiz ML; Chinchilla A; Ayuso JL; González Pinto A; Eguiluz I; Fernández A
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996; 24(4):165-72. PubMed ID: 8984849
[TBL] [Abstract][Full Text] [Related]
38. A comparative double-blind trial of fluspirilene and fluphenazine decanoate in the treatment of chronic schizophrenia.
Winter K; Fullerton AG; Hussain K; Tarlo L
Br J Clin Pract; 1973 Oct; 27(10):377-80. PubMed ID: 4601614
[No Abstract] [Full Text] [Related]
39. 12-month study of haloperidol decanoate in chronic schizophrenic patients.
Gelders YG; Reyntijens AJ; Ash CW; Aerts TJ
Int Pharmacopsychiatry; 1982; 17(4):247-54. PubMed ID: 7185769
[TBL] [Abstract][Full Text] [Related]
40. Experience with fluphenazine decanoate in the management of chronic schizophrenic outpatients.
Gaby N; Lefkowitz D; Israel JR
N C Med J; 1982 Sep; 43(9):641-4. PubMed ID: 6958987
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
